IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
CEO: Michael Erickson. Company website
IDEXX Laboratories, Inc. (IDXX) trades at $511.65, up 1.02% on the day, as of Sep 20, 2026 13:47 UTC.
IDEXX Laboratories, Inc. has a market capitalisation of $40.36B, calculated from the live IDXX share price and shares outstanding.
IDXX trades at a trailing P/E of 36.24, from earnings per share of $14.12 over the last twelve months.
IDEXX Laboratories, Inc. generated revenue of $4.55B over the trailing twelve months, which puts the stock at 8.86 times sales.
IDXX has traded between $500.61 and $769.98 over the past 52 weeks, and the last price is 33.6% below that high.
Yes. IDEXX Laboratories, Inc. keeps 25.03% of revenue as net income over the trailing twelve months.
Wall Street analysts rate IDXX Buy, with an average price target of $665.00, 30.0% above the current price.
IDEXX Laboratories, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Michael Erickson is the chief executive of IDEXX Laboratories, Inc., which employs 11,000 people.
QFI Terminal shows IDXX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IDXX in Terminal See plans